ArticleAmerican journal of translational research2024
PRKD3 promotes proliferation of liver cancer cells: a downstream proteomics profiling study.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning-driven evaluation of protein kinase D3 as a co-diagnostic biomarker in hepatocellular carcinoma.Journal of Zhejiang University. Science. B · 2026Article
- Pan-cancer landscape of protein kinase D3: An integrative TCGA multi-omics analysis of clinical, molecular, and immunological roles.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProtein kinase D 3 (PRKD3), a serine/threonine protein kinase, functions as a crucial regulator across numerous cancer types. However, its regulatory function and mechanism in hepatocellular carcinoma (HCC) proliferation remain unclear.
methodsA PRKD3 knockdown cell line was constructed to assess the effects of PRKD3 on proliferation of HCC cells using cell counting kit-8 (CCK-8) assay, 5-Ethynyl-2'-deoxyuridine (EdU) assay, clonogenic assay, and flow cytometry. Proteomic changes in liver cancer cells before and after PRKD3 knockdown were analyzed using 4D-lablefree technology.
resultsAnalysis of The Cancer Genome Atlas (TCGA) dataset revealed abnormal PRKD3 expression in HCC, associated with poorer prognosis and specific pathological types. Results from the CCK-8 assay showed a marked reduction in the proliferation of Huh7 cells (
conclusionThis study elucidates the inhibitory effect of PRKD3 knockdown on HCC proliferation and unveils the proteomic features of PRKD3 regulation. CDK4, SERPINE1, SQSTM1, RAB8A, and NRBF2 may serve as key proteins in PRKD3's regulatory pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.